Literature DB >> 7972127

Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.

C C Broder1, P L Earl, D Long, S T Abedon, B Moss, R W Doms.   

Abstract

A majority of monoclonal antibodies (mAbs) raised against soluble oligomeric human immunodeficiency virus type 1 isolate IIIB (HIV-1IIIB) envelope (env) glycoprotein reacted with conformational epitopes within the gp120 or gp41 subunits. Of 35 mAbs directed against gp41, 21 preferentially reacted with oligomeric env. A subset of these mAbs reacted only with env oligomers (oligomer-specific mAbs). In contrast, only 1 of 27 mAbs directed against the gp120 subunit reacted more strongly with env oligomers than with monomers, and none were oligomer-specific. However, 50% of anti-gp120 mAbs preferentially recognized monomeric env, suggesting that some epitopes in gp120 are partially masked or altered by intersubunit contacts in the native env oligomer. Two mAbs to oligomer-dependent epitopes in gp41 neutralized HIV-1IIIB and HIV-1SF2, and binding of these mAbs to env was blocked by preincubation with HIV-1-positive human serum. Thus, immunization with soluble, oligomeric env elicits antibodies to conserved, conformational epitopes including a newly defined class of neutralizing antibodies that bind to oligomer-specific epitopes in gp41, and may also minimize the production of antibodies that preferentially react with monomeric env protein.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7972127      PMCID: PMC45299          DOI: 10.1073/pnas.91.24.11699

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual.

Authors:  A T Profy; P A Salinas; L I Eckler; N M Dunlop; P L Nara; S D Putney
Journal:  J Immunol       Date:  1990-06-15       Impact factor: 5.422

2.  Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.

Authors:  K S Steimer; C J Scandella; P V Skiles; N L Haigwood
Journal:  Science       Date:  1991-10-04       Impact factor: 47.728

3.  gp160, the envelope glycoprotein of human immunodeficiency virus type 1, is a dimer of 125-kilodalton subunits stabilized through interactions between their gp41 domains.

Authors:  D J Thomas; J S Wall; J F Hainfeld; M Kaczorek; F P Booy; B L Trus; F A Eiserling; A C Steven
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

4.  Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro.

Authors:  J Cordell; J P Moore; C J Dean; P J Klasse; R A Weiss; J A McKeating
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

5.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.

Authors:  M Thali; U Olshevsky; C Furman; D Gabuzda; M Posner; J Sodroski
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

6.  Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody.

Authors:  D D Ho; J A McKeating; X L Li; T Moudgil; E S Daar; N C Sun; J E Robinson
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

7.  C-terminal fragments of gp120 and synthetic peptides from five HTLV-III strains: prevalence of antibodies to the HTLV-III-MN isolate in infected individuals.

Authors:  Y Devash; T J Matthews; J E Drummond; K Javaherian; D J Waters; L O Arthur; W A Blattner; J R Rusche
Journal:  AIDS Res Hum Retroviruses       Date:  1990-03       Impact factor: 2.205

8.  Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein.

Authors:  P L Earl; B Moss; R W Doms
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

9.  Mutations within the human immunodeficiency virus type 1 gp160 envelope glycoprotein alter its intracellular transport and processing.

Authors:  R L Willey; T Klimkait; D M Frucht; J S Bonifacino; M A Martin
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

10.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  55 in total

1.  Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.

Authors:  X Yang; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.

Authors:  X Yang; L Florin; M Farzan; P Kolchinsky; P D Kwong; J Sodroski; R Wyatt
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.

Authors:  A L Edinger; M Ahuja; T Sung; K C Baxter; B Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Basic problems of serological laboratory diagnosis.

Authors:  W Fierz
Journal:  Mol Biotechnol       Date:  1999-12-01       Impact factor: 2.695

6.  Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events.

Authors:  B J Doranz; S S Baik; R W Doms
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Elaine Kan; Michael Vajdy; Ying Lian; Susan Hilt; Loic Martin; Claudio Vita; Ping Zhu; Kenneth H Roux; Lucia Vojtech; David C Montefiori; John Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

Authors:  A Trkola; A B Pomales; H Yuan; B Korber; P J Maddon; G P Allaway; H Katinger; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies.

Authors:  Wen Yuan; Xing Li; Marta Kasterka; Miroslaw K Gorny; Susan Zolla-Pazner; Joseph Sodroski
Journal:  AIDS Res Hum Retroviruses       Date:  2009-03       Impact factor: 2.205

10.  Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

Authors:  Joseph F Bower; Xinzhen Yang; Joseph Sodroski; Ted M Ross
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.